What type of new anti-cancer targeted drugs does Tarlatamab belong to?

Tarlatamab (Tarlatamab) is a new anti-cancer targeted drug that has attracted much attention in recent years. It mainly targets neuroendocrine tumors such as small cell lung cancer (SCLC). It is a bispecific Tcell connector (BiTE) whose mechanism is different from traditional chemotherapy or single targeted therapy. Tarlatamabcan simultaneously bind to DLL3 protein on the surface of tumor cells and TCD3 receptor, thereby activating T cells to accurately kill cancer cells expressing DLL3, bringing new hope to patients with advanced and refractory cancers.

DLL3 (Delta-like ligand 3) is a protein with very low expression in normal tissues, but is highly expressed in small cell lung cancer and other neuroendocrine tumors. Therefore, DLL3 has become an ideal tumor target. TarlatamabBy binding to DLL3, it guides T cells into the tumor microenvironment and induces T cells to release cytotoxic factors, thereby specifically killing cancer cells. This mechanism is not only accurate, but also reduces the impact on normal tissues and has better safety.

Tarlatamabhas shown good therapeutic prospects in multiple clinical studies. In a clinical trial for recurrent small cell lung cancer, the drug showed high objective response and disease control rates, especially in patients who failed to respond to traditional treatments. In addition, due to its novel mechanism of action, it has also been included in research plans to explore other DLL3-positive solid tumors, such as neuroendocrine prostate cancer.

In general, Tarlatamab represents a new class of bispecific antibody drugs with both targeting and immune activation functions, filling the gap in the treatment of small cell lung cancer. Its ongoing phase III clinical trials will further verify its efficacy and safety, and is expected to become an important treatment for anti-DLL3-positive cancers in the future. For patients who lack effective treatment options, Tarlatamab offers new hope and direction.

Reference materials:https://www.drugs.com